>
United Nations, World Bank Target Small-Scale Chicken Farms in Bird Flu 'Global Summit'
Elon Musk posted this by Scott Adams, on all of the Leftists busted, think on it!
Tulsi Gabbard has tough words for the "empty" people who celebrated Charlie Kirk's mur
Sharaa says agreement with Moscow enabled swift fall of Assad
ORNL tackles control challenges of nuclear rocket engines
Tesla Megapack Keynote LIVE - TESLA is Making Transformers !!
Methylene chloride (CH2Cl?) and acetone (C?H?O) create a powerful paint remover...
Engineer Builds His Own X-Ray After Hospital Charges Him $69K
Researchers create 2D nanomaterials with up to nine metals for extreme conditions
The Evolution of Electric Motors: From Bulky to Lightweight, Efficient Powerhouses
3D-Printing 'Glue Gun' Can Repair Bone Fractures During Surgery Filling-in the Gaps Around..
Kevlar-like EV battery material dissolves after use to recycle itself
Laser connects plane and satellite in breakthrough air-to-space link
Lucid Motors' World-Leading Electric Powertrain Breakdown with Emad Dlala and Eric Bach
A 13-year-old girl who was left completely bald from her alopecia has made an incredible transformation after taking an arthritis drug.
The unidentified teenager, from Brazil, had slowly been losing her hair for five years and standard medications failed to help. Doctors tried tofacitinib as a last-resort.
Tests of the drug, marketed as Xeljanz, have shown it can help alopecia patients regrow their hair – but it is not yet licensed as a conventional treatment.
After just four months, the girl regained a significant amount of her hair. She was left with thick, brown locks within two years of taking tofacitinib.
The results add to the evidence that the drug could offer hope for millions of patients around the world with alopecia, who have slim chances of making a full recovery.
Tofacitinib is routinely given to patient with rheumatoid arthritis, which is caused by inflammation. Dermatologists say the type of alopecia the girl had is caused by the same process.
Medical student Rachel Berbert Ferreira, at Centro Universitario Cesumar, was the senior author of the paper in Clinical Case Reports.